Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lear Corporation stock logo
LEA
Lear
$138.89
+0.9%
$123.46
$86.14
$142.84
$6.96B1.21569,704 shs323,647 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$112.75
-0.6%
$116.31
$73.31
$125.14
$278.51B0.1810.96 million shs2.19 million shs
Novartis AG stock logo
NVS
Novartis
$150.31
+0.4%
$151.61
$106.71
$170.46
$286.81B0.462.04 million shs824,879 shs
Zoetis Inc. stock logo
ZTS
Zoetis
$74.27
-0.1%
$114.33
$73.98
$172.23
$31.11B0.874.97 million shs5.22 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lear Corporation stock logo
LEA
Lear
+0.93%+0.08%+11.75%+0.69%+44.14%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.04%+0.04%-5.51%-4.77%+48.22%
Novartis AG stock logo
NVS
Novartis
+1.03%+0.91%-2.97%-7.08%+40.13%
Zoetis Inc. stock logo
ZTS
Zoetis
-3.37%-33.37%-38.11%-40.82%-53.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lear Corporation stock logo
LEA
Lear
$138.89
+0.9%
$123.46
$86.14
$142.84
$6.96B1.21569,704 shs323,647 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$112.75
-0.6%
$116.31
$73.31
$125.14
$278.51B0.1810.96 million shs2.19 million shs
Novartis AG stock logo
NVS
Novartis
$150.31
+0.4%
$151.61
$106.71
$170.46
$286.81B0.462.04 million shs824,879 shs
Zoetis Inc. stock logo
ZTS
Zoetis
$74.27
-0.1%
$114.33
$73.98
$172.23
$31.11B0.874.97 million shs5.22 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lear Corporation stock logo
LEA
Lear
+0.93%+0.08%+11.75%+0.69%+44.14%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.04%+0.04%-5.51%-4.77%+48.22%
Novartis AG stock logo
NVS
Novartis
+1.03%+0.91%-2.97%-7.08%+40.13%
Zoetis Inc. stock logo
ZTS
Zoetis
-3.37%-33.37%-38.11%-40.82%-53.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lear Corporation stock logo
LEA
Lear
2.33
Hold$140.541.19% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.1813.68% Upside
Novartis AG stock logo
NVS
Novartis
2.31
Hold$141.20-6.06% Downside
Zoetis Inc. stock logo
ZTS
Zoetis
2.40
Hold$141.2590.19% Upside

Current Analyst Ratings Breakdown

Latest LEA, NVS, ZTS, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Lear Corporation stock logo
LEA
Lear
Boost Price TargetOverweight$152.00 ➝ $153.00
5/8/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetNeutral$130.00 ➝ $99.00
5/8/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Set Price Target$105.00
5/8/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetOverweight$190.00 ➝ $130.00
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/5/2026
Lear Corporation stock logo
LEA
Lear
Boost Price TargetSector Perform$134.00 ➝ $138.00
5/5/2026
Lear Corporation stock logo
LEA
Lear
Boost Price TargetEqual Weight$140.00 ➝ $150.00
5/4/2026
Lear Corporation stock logo
LEA
Lear
Reiterated RatingHold (C+)
5/4/2026
Lear Corporation stock logo
LEA
Lear
Set Price Target$133.00
5/4/2026
Lear Corporation stock logo
LEA
Lear
Reiterated RatingHold
5/4/2026
Lear Corporation stock logo
LEA
Lear
Set Price Target$130.00
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lear Corporation stock logo
LEA
Lear
$23.26B0.30$26.61 per share5.22$105.31 per share1.32
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.77B4.23$11.46 per share9.84$18.60 per share6.06
Novartis AG stock logo
NVS
Novartis
$56.58B5.07$10.89 per share13.80$20.40 per share7.37
Zoetis Inc. stock logo
ZTS
Zoetis
$9.53B3.27$7.30 per share10.17$7.71 per share9.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lear Corporation stock logo
LEA
Lear
$436.80M$10.0013.898.180.692.25%13.69%4.71%7/24/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5531.7711.542.5313.59%27.55%10.73%N/A
Novartis AG stock logo
NVS
Novartis
$13.98B$6.9821.5315.292.6024.87%38.82%15.16%7/21/2026 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.67B$6.0312.319.961.2627.80%66.85%18.79%N/A

Latest LEA, NVS, ZTS, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.60$1.53-$0.07$1.42$2.30 billion$2.26 billion
5/1/2026Q1 2026
Lear Corporation stock logo
LEA
Lear
$3.51$3.87+$0.36$3.34$5.84 billion$5.82 billion
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
4/27/2026Q1 2026
Novartis AG stock logo
NVS
Novartis
$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lear Corporation stock logo
LEA
Lear
$3.082.22%+24.74%30.80%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.403.02%+5.75%95.77%14 Years
Novartis AG stock logo
NVS
Novartis
$3.082.05%+5.28%44.13%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.122.85%+20.11%35.16%14 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lear Corporation stock logo
LEA
Lear
0.51
1.33
1.05
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Novartis AG stock logo
NVS
Novartis
0.96
0.85
0.65
Zoetis Inc. stock logo
ZTS
Zoetis
2.80
3.15
1.91

Institutional Ownership

CompanyInstitutional Ownership
Lear Corporation stock logo
LEA
Lear
97.04%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Lear Corporation stock logo
LEA
Lear
1.02%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novartis AG stock logo
NVS
Novartis
0.01%
Zoetis Inc. stock logo
ZTS
Zoetis
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lear Corporation stock logo
LEA
Lear
164,30050.10 million49.58 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,500419.23 million418.31 millionOptionable

Recent News About These Companies

Zoetis (NYSE:ZTS) Director Purchases $151,760.00 in Stock
Pacer Advisors Inc. Raises Stake in Zoetis Inc. $ZTS
Zoetis Stock: Analyst Estimates & Ratings
Zoetis (NYSE:ZTS) Sets New 1-Year Low on Analyst Downgrade
Zoetis (NYSE:ZTS) Posts Earnings Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Lear stock logo

Lear NYSE:LEA

$138.89 +1.28 (+0.93%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lear Corporation designs, develops, engineers, manufactures, assembles, and supplies automotive seating, and electrical distribution systems and related components for automotive original equipment manufacturers in North America, Europe, Africa, Asia, and South America. Its Seating segment offers seat systems, seat subsystems, keyseat components, seat trim covers, seat mechanisms, seat foams, and headrests, as well as surface materials, such as leather and fabric for automobiles and light trucks, compact cars, pick-up trucks, and sport utility vehicles. The company's E-Systems segment provides electrical distribution and connection systems that route electrical signals and networks; and manage electrical power within the vehicle for various powertrains. This segment's products comprise wire harnesses, terminals and connectors, engineered components, and junction boxes; electronic system products, including body domain control modules, smart and passive junction boxes, gateway and communication modules, integrated power modules, and high voltage switching and power control systems. It also offers software and connected services comprising Xevo Market, an in-vehicle commerce and service platform; and software and services for the cloud, vehicles, and mobile devices. In addition, this segment provides cybersecurity software; advanced vehicle positioning for automated and autonomous driving applications; and short-range communication and cellular protocols for vehicle connectivity. It offers its products and services under the XEVO, GUILFORD, EAGLE OTTAWA, ConfigurE+, INTUTM, LEAR CONNEXUSTM, EXO, JOURNEYWARE, ProTec, SMART JUNCTION BOX, STRUCSURE, AVENTINO, and TeXstyle brands. Lear Corporation was founded in 1917 and is headquartered in Southfield, Michigan.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$112.75 -0.70 (-0.61%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis stock logo

Novartis NYSE:NVS

$150.31 +0.56 (+0.38%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Zoetis stock logo

Zoetis NYSE:ZTS

$74.27 -0.07 (-0.10%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.